GlassScriptPhysician profile
Adel M Salama
NPI 1003807496
$1,239.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.09 · 2020: $325 · 2021: $560 · 2022: $120 · 2023: $158 · 2024: $15.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $149.59 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $142.73 | 2020-2021 | |
| Amarin Pharma, INC. | $134.96 | 2019-2022 | |
| Novo Nordisk INC | $93.29 | 2020-2021 | |
| Corium, LLC | $73.77 | 2022-2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $61.99 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $57.71 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $56.10 | 2020-2021 | |
| Lilly USA, LLC | $54.66 | 2021-2022 | |
| Eisai INC. | $54.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.55 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $42.84 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $41.83 | 2021 | |
| Astellas Pharma US INC | $30.26 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $25.91 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $23.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.28 | 2020 | |
| Abbott Laboratories | $20.68 | 2021 | |
| Biocryst US Sales Co., LLC | $16.77 | 2021 | |
| Merck Sharp & Dohme LLC | $15.09 | 2021 | |
| Mannkind Corporation | $15.01 | 2020 | |
| Glaxosmithkline, LLC. | $14.84 | 2023 | Arexvy, Shingrix |
| Seqirus USA INC | $14.12 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.04 | 2021 | |
| Abbvie INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Salama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.